Journal
FRONTIERS IN BIOSCIENCE-LANDMARK
Volume 17, Issue -, Pages 1120-1139Publisher
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/3977
Keywords
RUNX1; AML1; CBFA2; RUNX1-ETO; AML1-ETO; RUNX1-RUNX1T1; Hematopoiesis; Hematopoietic Stem Cells; Leukemia; AML; Leukemogenesis; Mouse Models; Review
Categories
Funding
- National Institutes of Health [CA096735, CA10450, DK080665]
- NATIONAL CANCER INSTITUTE [R01CA096735] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL103106] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK080665] Funding Source: NIH RePORTER
Ask authors/readers for more resources
RUNX1 is a transcription factor that regulates critical processes in many aspects of hematopoiesis. RUNX1 is also integral in defining the definitive hematopoietic stem cell. In addition, many hematological diseases like myelodysplastic syndrome and myeloproliferative neoplasms have been associated with mutations in RUNX1. Located on chromosomal 21, the RUNX1 gene is involved in many forms of chromosomal translocations in leukemia. t(8,21) is one of the most common chromosomal translocations found in acute myeloid leukemia (AML), where it results in a fusion protein between RUNX1 and ETO. The RUNX1-ETO fusion protein is found in approximately 12% of all AML patients. In this review, we detail the structural features, functions, and models used to study both RUNX1 and RUNX1-ETO in hematopoiesis over the past two decades.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available